

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Biomarin Pharmaceutical
INC
105 DIGITAL DRIVE
NOVATO, CA 94949
USA

Biomarin Pharmaceutical INC TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Biomarin Pharmaceutical INC has been TOP Rated at rank 19 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



B:OMARIN®

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Biomarin Pharmaceutical INC. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



B:OMARIN®

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Biomarin Pharmaceutical INC (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Biomarin Pharmaceutical INC
Amount	USD 9,900
Order no.	2026-0001048477

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Biomarin Pharmaceutical INC

Date, location, name



The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 6.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 368%, being 138% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	3,953,490
Cost of Goods Sold	717,442
Intangible Assets	410,036
Liabilities, Current	759,031
Liabilities, Non-Current	150,816
Other Assets	2,277,988
Other Compr. Net Income	-75,126
Other Expenses	163,864
Other Liabilities	597,176
Other Net Income	83,901
Other Revenues	3,221,253
Property and Equipment	952,508
Research and Development	921,930
Selling, General and Administrative Expense	1,153,017

Output Variable	Value in 1000 USD
Assets	7,594,022
Liabilities	1,507,023
Expenses	2,956,253
Revenues	3,221,253
Stockholders Equity	6,086,999
Net Income	348,901
Comprehensive Net Income	311,338
BaseVar	7,718,789
ECR before Limited Liability	298%
Economic Capital Ratio	368%